BREZTRI breathes new life into COPD management
NCT ID NCT06422676
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 200 people with moderate to severe COPD who started taking the triple-combination inhaler BREZTRI. Researchers tracked changes in symptoms and lung function over 24 weeks in routine doctor visits. The goal was to see how the medicine performs outside of strict clinical trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Blagoveshchensk, Russia
-
Research Site
Kazan', Russia
-
Research Site
Krasnodar, Russia
-
Research Site
Krasnoyarsk, Russia
-
Research Site
Moscow, Russia
-
Research Site
Nizhny Novgorod, Russia
-
Research Site
Novosibirsk, Russia
-
Research Site
Omsk, Russia
-
Research Site
Rostov-on-Don, Russia
-
Research Site
Ryazan, Russia
-
Research Site
Saint Petersburg, Russia
-
Research Site
Ufa, Russia
-
Research Site
Volgograd, Russia
-
Research Site
Yekaterinburg, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart breathing machines at home: a new way to predict COPD crises?
- Breathing easy? new X-Ray method may spot COPD decline early
- Could a common heart drug cut COPD hospitalizations?
- Which inhaler breathes better? a Head-to-Head COPD showdown
- Could tiny lung valves revive heart and muscle strength in COPD?
- One lung or two? surgery trial aims to find the best approach for severe COPD